0001062822FALSE00010628222021-07-302021-07-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________

FORM 8-K
__________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2021

Lexicon Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-30111 76-0474169
(State or other jurisdiction of
incorporation or organization)
(Commission File Number) (I.R.S. Employer
Identification Number)

2445 Technology Forest Blvd., 11th Floor
The Woodlands, Texas 77381
(Address of principal executive offices and Zip Code)

(281) 863-3000
(Registrant’s telephone number, including area code)

8800 Technology Forest Place
The Woodlands, Texas 77381
(Former address if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.001 LXRX The Nasdaq Global Select Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02    Results of Operation and Financial Condition

On July 30, 2021, we issued a press release to report our financial results for the quarter ended June 30, 2021 and held a conference call to discuss the financial results and to provide a business update. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1 and a transcript of the conference call is attached to this current report on Form 8-K as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Information Regarding Forward-Looking Statements

The press release and transcript attached as Exhibits 99.1 and 99.2, respectively, each contain forward-looking statements within the meaning of the federal securities laws. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond our control. These risks include, but are not limited to, those identified in our annual report on Form 10-K and our other filings with the Securities and Exchange Commission. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. We do not undertake any obligation to update such forward-looking statements as a result of new information, future events or otherwise.


Item 9.01    Financial Statements and Exhibits

(d)    Exhibits

Exhibit No. Description
99.1
99.2
EX-104 Cover Page Interactive Data File (embedded within the Inline XBRL document)




Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Lexicon Pharmaceuticals, Inc.
Date: August 2, 2021 By: /s/ Brian T. Crum
Brian T. Crum
Vice President and General Counsel




Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Lexicon Pharmaceuticals Charts.
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Lexicon Pharmaceuticals Charts.